These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 25483462

  • 21. Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.
    Gao D, Yang H, Deng B, Yin G, Song W, Zhang H, Li Y.
    Hum Vaccin Immunother; 2016 Oct 02; 12(10):2634-2639. PubMed ID: 27348250
    [Abstract] [Full Text] [Related]

  • 22. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

  • 23. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
    Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM.
    Vaccine; 2011 Nov 28; 29(51):9544-50. PubMed ID: 21986218
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.
    Vaccine; 2011 Aug 05; 29(34):5666-74. PubMed ID: 21699951
    [Abstract] [Full Text] [Related]

  • 25. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.
    Hum Vaccin Immunother; 2014 May 01; 10(2):441-8. PubMed ID: 24240428
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 01; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 28. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    J Infect Dis; 2013 Jun 15; 207(12):1878-87. PubMed ID: 23470848
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA, Albano FR, Airey J, Sawlwin DC, Graves Jones A, Matassa V, Heijnen E, Edelman J, Marshall GS.
    Vaccine; 2019 Jan 07; 37(2):343-351. PubMed ID: 30057283
    [Abstract] [Full Text] [Related]

  • 30. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.
    Vaccine; 2014 May 01; 32(21):2507-17. PubMed ID: 24120672
    [Abstract] [Full Text] [Related]

  • 31. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 32. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.
    Hum Vaccin Immunother; 2015 Sep 25; 11(10):2370-5. PubMed ID: 26114800
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Sep 25; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 34. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP, Robertson CA, Talbot HK, Decker MD.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2058-2064. PubMed ID: 28700265
    [Abstract] [Full Text] [Related]

  • 35. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 36. A randomized, controlled, blinded study of the safety, immunogenicity and batch consistency of Aleph inactivated split influenza vaccine made in China in Chinese people.
    Li S, Li L, Ai X, Yang L, Bai Y, Wang Z, Han H, Lu Q, Luo F, Zhang Z, Liu C, Xiao J, Shi N.
    Hum Vaccin Immunother; 2014 Nov 21; 10(3):557-65. PubMed ID: 24301228
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y, Shao M, Hu Y, Liang Q, Jia N, Chu K, Xu L, Li J, Li C, Zhu F.
    Hum Vaccin Immunother; 2020 Jul 02; 16(7):1691-1698. PubMed ID: 32347785
    [Abstract] [Full Text] [Related]

  • 38. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age.
    Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM.
    Hum Vaccin Immunother; 2013 Sep 02; 9(9):1978-88. PubMed ID: 23782962
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.
    Song JY, Cheong HJ, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Noh JY, Choi WS, Kim H, Kim KH, Kim WJ.
    Vaccine; 2015 Oct 05; 33(41):5437-5444. PubMed ID: 26314625
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.